| answer text |
<p>The National Institute for Health and Care Excellence (NICE) is reviewing its methods
for the development of technology appraisal and highly specialised technology recommendations
in line with the commitment in the 2019 voluntary scheme for branded medicines pricing
and access. The scheme also states the Government’s expectations for the review as
follows: ‘“The Department expects that any future changes to NICE methods and processes
would respond to the new types of innovation coming to the market, be consistent with
improving the health gain achieved by spending on new innovative medicines, and support
faster adoption of the most clinically and cost effective medicines.”’</p><p> </p><p><strong>
</strong></p><p><strong> </strong></p>
|
 |
